052nok
-4,7 %
Date:2025-11-24Time:18:00:00Latest report:Q2-2024List:Oslo BorsTicker:ONCIN
Market Cap:82 mnokEnterprise Value:16 mnokNet Sales:5,41 mnokEarnings:-107,6 mnokEmployees:0ISIN:NO0013251173

Ratios

10-year key figure history for Oncoinvent turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Oncoinvent with index and moving average MA50 and MA200.

Stockprice:0,52
MA50:1,08
MA200:1,78
Price/MA200:-70,5 %
RSI (14):24,3
Price/MA50:-51,5 %

Description

Oncoinvent is a clinical phase radiopharmaceutical company developing treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver radiation directly to cancer cells. The Company's product candidate, Radspherin®, is an alpha radiation therapy candidate designed for the local treatment of cancer that has spread to body cavities. Oncoinvent has its headquarters in Oslo.

Biotechnology